Jazz Pharmaceuticals Announced Upcoming Investor Events
Dublin - Jazz Pharmaceuticals plc (NASDAQ: JAZZ) recently shared plans for its participation in significant investor gatherings aimed at enhancing shareholder engagement and transparency.
Zanidatamab Investor Webcast
The first event will be an investor webcast scheduled for January 9, 2026, at 6:30 a.m. PT / 3:30 p.m. GMT. This presentation will focus on the results from the Phase 3 zanidatamab HERIZON-GEA-01 trial, which holds promise for advanced cancer treatments. Alongside the company's senior management, Dr. Geoffrey Ku, a specialist from a renowned cancer center, will provide insights during the session. The webcast occurs after an important presentation at an esteemed oncology symposium on January 8, 2026.
J.P. Morgan Healthcare Conference Participation
Following the zanidatamab webcast, Jazz Pharmaceuticals will also be part of the prestigious 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. At 11:15 a.m. PST / 7:15 p.m. GMT, Renee Gala, the president and CEO, will deliver a corporate presentation outlining the company's strategic direction and provide an update on current operations and future prospects.
Accessing the Presentations
Investors can access audio webcasts of both events through the Investors section of the Jazz Pharmaceuticals website. A replay of these presentations will also be available for 30 days, allowing participants to catch up on important updates and information shared during the events.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a leading global biopharmaceutical company committed to transforming the lives of patients through innovative medical solutions. The company focuses on developing groundbreaking medicines for serious conditions that often lack effective treatments. Jazz's diverse portfolio includes renowned therapies addressing sleep disorders, epilepsy, and an expanding range of cancer therapies. The driving force behind their success is a commitment to patient-focused research and development, leading to the creation of many innovative products that improve lives worldwide. Headquartered in Dublin, Ireland, Jazz operates with laboratories, manufacturing sites, and staff across various countries, striving to deliver effective healthcare solutions globally.
Contact Information
Investor Relations:
Jack Spinks
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
Ireland, +353 1 634 3211
U.S., +1 650 496 2717
Media Inquiries:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
Ireland, +353 1 637 2141
U.S., +1 215 867 4948
Frequently Asked Questions
What are the key events Jazz Pharmaceuticals is participating in?
Jazz Pharmaceuticals will be involved in an investor webcast regarding the Phase 3 zanidatamab trial and the J.P. Morgan Healthcare Conference.
Who will present at the zanidatamab webcast?
Senior management from Jazz Pharmaceuticals and Dr. Geoffrey Ku will provide insights during the zanidatamab webcast.
When will the J.P. Morgan Healthcare Conference presentation take place?
The presentation will occur on January 13, 2026, at 11:15 a.m. PST / 7:15 p.m. GMT.
Where can I find the recordings of the events?
Recordings of the webcasts will be available on the Investors section of the Jazz Pharmaceuticals website for 30 days post-event.
What is Jazz Pharmaceuticals' mission?
Jazz aims to innovate and create transformative therapies for patients, focusing on serious conditions and improving their quality of life.
